Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ABL1
REST API REST API
Homo sapiens
ABL1 is differentially expressed in 262 experiments: 103 organism parts: liver, bone marrow, ... (101 more);, 160 disease states: normal, acute promyelocytic leukemia, ... (158 more);, 78 cell types 341 cell lines 45 compound treatments and 67 other conditions.
Synonyms p150, c-ABL, JTK7, ABL
Orthologs Abl1 (Rattus norvegicus)   ENSCING00000003255 (Ciona intestinalis)   ABL1 (Bos taurus)   Abl1 (Mus musculus)   ABL1 (Gallus gallus)   abl1 (Danio rerio)   Abl (Drosophila melanogaster)   abl1 (Xenopus laevis)   ABL1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, regulation of cell adhesion, DNA binding, protein binding, actin monomer binding, regulation of transcription, DNA-dependent, cytoplasm, DNA damage response, signal transduction resulting in induction of apoptosis, membrane, SH3 domain binding, peptidyl-tyrosine phosphorylation, protein tyrosine kinase activity, blood coagulation, protein domain specific binding, positive regulation of apoptosis, regulation of autophagy, ATP binding, actin cytoskeleton organization, magnesium ion binding, axon guidance, actin cytoskeleton, protein modification process, regulation of cell cycle, nucleus, manganese ion binding, muscle cell differentiation, mismatch repair, receptor activity, nucleotide binding, kinase activity, protein serine/threonine kinase activity, perinuclear region of cytoplasm, protein C-terminus binding, non-membrane spanning protein tyrosine kinase activity, protein kinase activity, nucleolus, nuclear membrane, mitochondrion, proline-rich region binding, regulation of endocytosis, nicotinate-nucleotide adenylyltransferase activity, DNA damage induced protein phosphorylation, positive regulation of oxidoreductase activity, positive regulation of muscle cell differentiation, mitogen-activated protein kinase binding, protein phosphorylation, regulation of transcription involved in S phase of mitotic cell cycle, negative regulation of protein serine/threonine kinase activity, regulation of cell motility, signal transduction in response to DNA damage, regulation of actin cytoskeleton reorganization, regulation of response to DNA damage stimulus
InterPro Term SH2, SH3_domain, F-actin_binding, Prot_kinase_cat_dom, SH3_2, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom, SH3_3
UniProt Accession P00519, Q13688, Q59F19, Q59FK4
Gene-Disease Assocation LEUKEMIA, CHRONIC MYELOID; CML
Search EB-eye ENSG00000097007
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-4717, ... (38 experiments)

Factor Value U/D Experiments
BT474
3
E-MEXP-440, E-MTAB-62, E-MTAB-37
K562
3
E-MTAB-37, E-GEOD-96, E-GEOD-24147
MCF-7
1
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-5823, E-GEOD-19639
Daudi
2
E-GEOD-96, E-MTAB-37
HL-60
2
E-GEOD-96, E-GEOD-5258
PC3
2
E-GEOD-5258, E-MEXP-2034
335 more value(s).


Cell type

studied in E-TABM-40, E-MEXP-1121, E-GEOD-21668, E-GEOD-3920, E-GEOD-360, ... (44 experiments)

Factor Value U/D Experiments
hematopoietic stem cell
2
E-MEXP-1403, E-MEXP-872
fibroblast
2
E-GEOD-3920, E-GEOD-3204
CD4+ T cell
1
2
E-GEOD-16190, E-MTAB-24, E-MTAB-25
macrophage
1
2
E-GEOD-5099, E-GEOD-360, E-GEOD-8286
adipocyte
1
E-AFMX-5
alveolar space neutrophil
1
E-GEOD-2322
72 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-MEXP-1121, ... (54 experiments)

Factor Value U/D Experiments
control
1
3
E-GEOD-21912, E-GEOD-16363, E-GEOD-3185, E-GEOD-20295
acute promyelocytic leukemia
1
3
E-GEOD-96, E-MTAB-62, E-GEOD-995, E-GEOD-1729
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
neuroblastoma
2
E-MTAB-37, E-MTAB-62
154 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-697, E-TABM-782, E-GEOD-5824, E-MEXP-1958, ... (27 experiments)

Factor Value U/D Experiments
none
2
7
E-GEOD-412, E-GEOD-5824, E-MEXP-1958, E-MEXP-1230, E-GEOD-995, ... (9 experiments)
control
2
E-GEOD-995, E-GEOD-5339
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
U0126
1
E-GEOD-697
4OH-tamoxifen
1
E-GEOD-2292
resveratrol
1
E-TABM-782
39 more value(s).


Biosource provider

studied in E-GEOD-14359

Factor Value U/D Experiments
Provitro GmbH, Berlin, Germany
1
E-GEOD-14359
Charite Universitätsmedizin Berlin
1
E-GEOD-14359


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-1563, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-MEXP-480, E-GEOD-3325, E-GEOD-22148, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-GEOD-17385, E-GEOD-20847, E-GEOD-6431, ... (8 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-2292, E-TABM-321, E-TABM-868, E-TABM-601, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-TABM-127, E-GEOD-20540, E-MEXP-1446, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-2466, E-GEOD-1926, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-2077, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426, E-TABM-84

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-6434, E-GEOD-17636, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-1880, E-GEOD-19246

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-GEOD-1703, E-MEXP-1509, E-GEOD-1676, E-MEXP-548, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-MEXP-973, E-GEOD-15799, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.257 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM